Oncotelic Presenting at MedInvest Pharmaceutical and Biotechnology Investor Conference
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against…
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against…
In the press release published on February 22, 2022, the appendix with the notice was…
The First and Only FDA-Approved, Ready-to-Use Oral Solution for the Acute Treatment of Migraine with…
Newly published data demonstrates substantial cross-reactivity against multiple variants of COVID-19 S-only candidate is believed…
REDWOOD CITY, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — AmMax Bio, Inc. (“AmMax”), a private…
Appointment accelerates Company’s development roadmap in targeted therapies for neuropsychiatric disorders The Head of the…
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage…
Pivotal Phase 3 data from the NORSE TWO registration trial to be presented by Lawrence…
Ceremony Recognizes Importance of Biopharma Industry and Advocacy Group Collaboration to Address Needs for New…
SAN DIEGO, Feb. 24, 2022 (GLOBE NEWSWIRE) — Codex DNA, Inc. (Nasdaq: DNAY), a pioneer…
SOUTH SAN FRANCISCO, Calif., Feb. 24, 2022 (GLOBE NEWSWIRE) — Pliant Therapeutics, Inc. (Nasdaq: PLRX),…
OT-101 is Oncotelic’s RNA Therapeutic Against TGF-β OT-101 has completed over six clinical trials against…
Reports full year 2021 revenue of $85.4 million, above pre-announced preliminary range Reiterates 2022 revenue…
Poster Presentation: Combination immunotherapy and HTT-lowering in humanized HD mice, Wednesday, March 2, 2022 ROCHESTER,…
JATENZO is the first and only FDA-approved oral softgel capsule for testosterone replacement therapy in…
FORT LAUDERDALE, Fla., Feb. 24, 2022 (GLOBE NEWSWIRE) — Motus GI Holdings, Inc., (NASDAQ: MOTS)…
SEATTLE and VANCOUVER, British Columbia, Feb. 24, 2022 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc….
CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company…
SAN FRANCISCO, Feb. 24, 2022 (GLOBE NEWSWIRE) — 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical…
CONSHOHOCKEN, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) — Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical…